Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Groningen – page 37

562 clinical trials in Groningen, The Netherlands across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Groningen at a glance
562
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

562 trials in Groningen

Open in trial search

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study to Identify Unknown Primary Cancer Using [18F]-AlF-FAPI-74 PET-CT for Patients with Carcinoma of Unknown Primary

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cardiac failure+1

Not recruiting

Study on Vericiguat for Children with Heart Failure from Left Ventricular Systolic Dysfunction

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rilvegostomig
  • Sponsor:AstraZeneca AB

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Groningen

What the registry says about research in the country

01 Cardiovascular Research

Advanced studies focusing on heart disease and cardiovascular conditions, including innovative treatments for ATTR amyloidosis and prevention strategies for heart failure.

  • Cardiomyopathy Treatments
  • Heart Failure Prevention
  • Peripheral Arterial Disease

Multiple trials exploring novel therapeutic approaches and preventive measures for various cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including melanoma and lung cancer, with particular focus on innovative treatment approaches and metastatic disease management.

  • Advanced Breast Cancer
  • Small Cell Lung Cancer
  • Brain Metastases

Investigation of targeted therapies and combination treatments for improved patient outcomes.

03 Metabolic Disorders

Clinical investigations focusing on obesity and type 2 diabetes, testing new therapeutic approaches for weight management and metabolic control.

  • Weight Management
  • Diabetes Treatment
  • Metabolic Health

Evaluation of novel medications combined with lifestyle interventions for optimal patient care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.